![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
News|Podcasts|August 29, 2021
OncView™ Podcast: Updates in Therapies for Relapsed/Refractory Follicular Lymphoma
Author(s)Matthew Fowler, Javier L. Munoz, MD, MS, FACP
This special episode of “Oncology Peer Review On-The-Go” includes a discussion on relapsed/refractory follicular lymphoma with Javier Munoz, MD, MS, FACP.
Advertisement
As part of its OncView™ video series, CancerNetwork® spoke with Javier Munoz, MD, MS, FACP, from the Mayo Clinic in Phoenix, Arizona, about updates in therapies for relapsed/refractory (R/R) follicular lymphoma (FL).
In the video series, Javier Munoz, MD, MS, FACP, discussed the following:
Current Treatment Options for Relapsed/Refractory Follicular Lymphoma Factors in Choosing R/R FL Treatments Treatment Options for Third-Line R/R FL Use of Tazemetostat for R/R FL Changes in Sequencing of R/R FL Therapies
To watch more videos in CancerNetwork®’s OncView™ series, visit
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
Advertisement
Related to this article
Posters highlighted sex-based differences in aggressive B-cell NHL, third-line therapies in aggressive BCL, and real-world safety with CD20/CD3 bispecifics.
Mary Jo Lechowicz, MD, discussed how pre-transplant depth of response informs the choice between autologous and allogeneic HSCT in T-cell lymphoma.
SOHO 2026 sessions covered chemoimmunotherapy in frontline DLBCL, treatment selection via molecular classifiers, and bispecific antibodies for unfit patients.
Jasmine Zain, MD, emphasized the importance of good patient counseling when outlining the potential risks of secondary T-cell malignancies following CAR T-cell therapy.
Adult T-cell lymphoma and leukemia may warrant up-front allogeneic transplant, according to Mary Jo Lechowicz, MD.
The IND clearance for IASO208, a CD20-targeted in vivo CAR-T therapy requiring no leukapheresis or lymphodepletion, enables advancement of a phase 1b trial.
The risk of infections with epcoritamab plus R2 appeared to level off after the first 4 cycles of therapy in the EPCORE FL-1 trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
COA Warns That Price Negotiation for Medicare Part B Drugs Threatens Community Oncology
3
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
4
Using Intrathecal Dendritic Cells for Leptomeningeal Disease From Breast Cancer
5